Which drug is classified as a leukotriene modifier?

Montelukast is classified as a leukotriene modifier, which means it works by blocking the action of leukotrienes, substances in the immune system that contribute to inflammation, bronchoconstriction, and mucus production in conditions such as asthma and allergic rhinitis. By inhibiting leukotriene receptors, montelukast helps to reduce the symptoms of asthma and improve lung function.

In contrast, prednisolone is a corticosteroid that acts on various inflammatory processes but does not specifically modify leukotriene activity. Budesonide is also a corticosteroid, primarily used to reduce inflammation in the airways, thus providing relief in conditions like asthma but not classified as a leukotriene modifier. Ipratropium bromide is an anticholinergic agent used to relieve bronchospasm in conditions like COPD, working through a different mechanism than leukotriene modification.

Montelukast's unique pathway and specific targeting of leukotrienes distinguishes it from these other medications, making it effective for managing asthma symptoms directly related to leukotriene levels.